What does this research mean for the field?

In acute myeloid leukemia, synergistic dysfunction in chromatin remodeling and Polycomb-mediated repression enables a core transcriptional network (centered on AFF1, TAL1, IKZF1, and GATA1) that hijacks TP53/FoxO signaling to drive oncogenesis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to identify the transcriptional networks influenced by epigenetic changes in acute myeloid leukemia.

June 1, 2026Open Access

An integrated multi-omics analysis reveals a core epigenetically-activated transcriptional network driving oncogenic signaling in acute myeloid leukemia

Key Points

This research aims to identify the transcriptional networks influenced by epigenetic changes in acute myeloid leukemia.
Employing an integrative bioinformatics strategy using transcriptomic data from distinct AML cell types.
Analyzing differentially expressed genes to create a 32-gene AML signature.
Validating core gene expression patterns through functional enrichment and PPI network analyses.
The 32-gene AML signature demonstrated strong enrichment in hematopoietic differentiation pathways.
Identified nine key hubs influencing transcriptional activity, revealing expression heterogeneity across AML subtypes.
Perturbation analysis indicated significant roles for chromatin remodeling and Polycomb repression in oncogenic signaling.

Abstract

Abstract Purpose Acute Myeloid Leukemia (AML) is driven by complex interactions between genetic mutations and epigenetic dysregulation. While alterations in chromatin modifiers are frequent, the precise downstream transcriptional networks they enable and how these networks execute the leukemogenic program remain incompletely defined. Methods We employed an integrative bioinformatics strategy. Transcriptomic data from GSE84881 (AML stromal cells) and GSE9476 (AML blasts) identified differentially expressed genes, refined via GeneCards and CellMarker to a 32-gene AML signature. Functional enrichment (GO/KEGG) and protein-protein interaction (PPI) network analyses followed. Core hubs were validated for spatial (single-cell t-SNE) and subtype-specific expression using the Hematologic Malignancy database. Perturbation analysis (GPSAdb2.0 BioTrigger) expanded the network, with pathway enrichment on responsive genes. Results The 32-gene signature enriched strongly in hematopoietic differentiation and unexpectedly in cross-lineage developmental pathways (e.g., gland, epithelial development). PPI topology revealed nine hubs: AFF1, TAL1, IKZF1, GATA1, NOTCH1, BCL2, IL1B, IRF4, ZAP70. Single-cell t-SNE showed distinct, non-overlapping localization patterns among AML subpopulations; box plots demonstrated marked expression heterogeneity across 26 molecular subtypes. Perturbation of these hubs generated a 500-gene set whose KEGG enrichment highlighted three interconnected layers: (i) Polycomb repression and ATP-dependent chromatin remodeling (epigenetic gatekeepers), (ii) FoxO signaling, cell cycle, and senescence (core oncogenic pathways), and (iii) broad cancer hallmarks including endocrine resistance and diverse solid tumor pathways. Conclusion We propose a hierarchical pathomechanism: synergistic dysfunction in chromatin remodeling and Polycomb-mediated repression establishes a permissive epigenomic landscape, enabling activation of an oncogenic transcriptional network (centered on AFF1, TAL1, IKZF1, GATA1). This network then hijacks TP53/FoxO signaling to drive cell cycle escape, apoptosis resistance, and metabolic adaptation. Our findings unify disparate molecular lesions into a coherent axis and suggest new therapeutic nodes.

Ask AI

Helpful

Bookmark

View Full Paper